Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs QUALCOMM, Inc. (QCOM) Price & Performance

Novartis AGTrade
QUALCOMM, Inc.Trade

Price performance (Past 24H)

Key statistics

Novartis AG vs QUALCOMM, Inc. — how do they compare? Novartis AG trades at $142.74 (market cap $268.57B), while QUALCOMM, Inc. trades at $176.8 (market cap $187.95B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and QUALCOMM, Inc. for 87 Days on average.

NVSQCOM
Market Cap
$268.57B$187.95B
Volume
1,532,5739,535,042
Sector
HealthTechnology
52-Week High
$168.62$251.10
52-Week Low
$121.80$124.07
Typical Hold Time
82 Days87 Days
Enterprise Value
$309.89B$194.92B
Dividend Yield
3.31%2.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.

Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.

QUALCOMM, Inc.

Qualcomm (QCOM) trades at $176.01, down 2.79% on the day, with a bearish technical signal but strong fundamentals including 21.01% net income margin and 33.75% ROE. Recent earnings show mixed results with Q2 2026 missing expectations, while the company benefits from diversification into AI data centers and automotive sectors. Analyst consensus price target stands at $204.48, representing 16% upside potential from current levels.

The stock presents a compelling opportunity with reasonable valuation (P/E 20.24) and transformative AI partnerships, particularly the Amazon AWS deal offering up to $60 billion in potential revenue. Key risks include smartphone market dependence and competitive pressures in AI chips. Wall Street sentiment leans positive with 43% buy ratings despite recent technical weakness.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NVS
100% Buy0% Sell
Avg holding period · 82 Days
QCOM
54% Buy46% Sell
Avg holding period · 87 Days

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS →

About QUALCOMM, Inc.

Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.

Read more on QCOM →